Neurologic Disorders Therapeutics Market by Application and Geography - Forecast and Analysis 2022-2026

According to Technavio's analyst, the neurologic disorders therapeutics market size is expected to be valued at USD 33.46 billion by 2026 with a progressing CAGR of 5.44%.

The neurologic disorders therapeutics market has been broadly categorized into the following demographic segmentations: 

• Application - CNS and PNS
• Geography - North America, Europe, Asia, and Rest of World (ROW)

What will the Neurologic Disorders Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Neurologic Disorders Therapeutics Market Size for the Forecast Period and Other Important Statistics

This neurologic disorders therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The neurologic disorders therapeutics market report offers information on several market vendors, including AbbVie Inc., Acadia Pharmaceuticals Inc., Acorda Therapeutics Inc., Bayer AG, Biogen Inc., Eisai Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Merck KGaA, Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and USWM LLC among others.

Neurologic Disorders Therapeutics Market: Key Drivers, Trends, and Challenges

The approval of novel drugs is notably driving the neurologic disorders therapeutics market growth, although factors such as the advent of neurostimulation devices may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the neurologic disorders therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Neurologic Disorders Therapeutics Market Driver

• One of the key drivers supporting the neurologic disorders therapeutics market growth is the approval of novel drugs.
• Several drugs have been approved for the treatment of various neurologic indications, such as schizophrenia, bipolar disorder, depression, ADHD, and OCD.
• For instance, in April 2021, the US FDA approved Qelbree of Supernus Pharmaceuticals for treating ADHD in children aged between 6 and 17 years, and it comes as a capsule taken daily.
• In 2021, FDA has approved two new antidepressant medications brexanolone and esketamine that represent new approaches to treating depression.
• Various other drugs have received marketing approval from the US FDA and the EMA for the treatment of indications such as ADHD, schizophrenia, and bipolar disorder. Thus, the rising number of drug approvals is expected to address the significant unmet need and, thus, contribute to the growth of the global neurologic disorders therapeutics market during the forecast period 

Key Neurologic Disorders Therapeutics Market Trend

• One of the key neurologic disorders therapeutics market trends contributing to the market growth is the advent of regenerative medicines.
• Stem cell therapy is a process of treating severe life-threatening indications using stem cells, such as mesenchymal stromal cells and embryonic stem cells. It is a type of regenerative medicine that uses stem cells and their derivatives, and it works by promoting the repair response of the diseased tissue and the dysfunctional tissue.
• Stem cell therapy involves the modification of donor cells in laboratories into specific types of cells, such as nerve cells. These cells are injected into the patient at the action site, and they stop and reverse the progression of the disease by replacing the mutated cells with healthy cells.
• Stem cell therapy is widely being researched for the treatment of neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease, and indications, such as MS. This, in turn, will propel the neurologic disorders therapeutics market growth during the forecast period.

Key Neurologic Disorders Therapeutics Market Challenge

• One of the factors challenging the neurologic disorders therapeutics market growth is the advent of neurostimulation devices.
• Based on advances in neuroscience, non-invasive neuromodulation devices are composed to gain clinical importance in the coming years and be of increasing interest to clinicians, healthcare systems, patients, industry, and payers.
• NeuroPace Inc. developed the RNS System, which is approved by the US FDA as an adjunctive treatment for adults with medically refractory partial seizures. The device is placed under the scalp within the skull and then connected to a neurostimulator. The activities of the brain are continuously monitored by the RNS System to detect the patterns for seizures, once the pattern is detected the neurostimulator sends brief impulses and disrupts the abnormal brain activity.
• The inclination of patients toward non-drug options for the treatment of various brain-related disorders is increasing.
• Ongoing research activities in the field and the recent approval of neuromodulation devices, as well as their rising use for the treatment of various neurologic disorders, will be challenges to the growth of the global neurologic disorders therapeutics market during the forecast period. 

This neurologic disorders therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global neurologic disorders therapeutics market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the neurologic disorders therapeutics market during the forecast period.

Who are the Major Neurologic Disorders Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• AbbVie Inc.
• Acadia Pharmaceuticals Inc.
• Acorda Therapeutics Inc.
• Bayer AG
• Biogen Inc.
• Eisai Co. Ltd.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• H Lundbeck AS
• Johnson and Johnson
• Merck KGaA
• Mylan NV
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB SA
• USWM LLC

This statistical study of the neurologic disorders therapeutics market encompasses successful business strategies deployed by the key vendors. The neurologic disorders therapeutics market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• AbbVie Inc. - The company offers solutions for neurologic disorders therapeutics to help improve the physical wellbeing of people. 
• Biogen Inc. - The company offers solutions for neurologic disorders which includes three neurological diseases, multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. 
• F. Hoffmann La Roche Ltd. - The company offers solutions for neurologic disorders by creating barriers that impact our ability to engage, to move, to remember and over time, can change or take away the unique qualities that make us who we are. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The neurologic disorders therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Neurologic Disorders Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the neurologic disorders therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Neurologic Disorders Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the neurologic disorders therapeutics market in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The strong dominance of generics will facilitate the neurologic disorders therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 had a negative impact on the regional market. . However, due to the pandemic, neurologic disorders have increased in people, mainly depression. According to worldwide data, COVID-19 triggers a 25% increase in the prevalence of anxiety and depression. Such factors will increase the demand for neurologic disorders therapeutics, thereby driving market growth in North America during the forecast period.

What are the Revenue-generating Application Segments in the Neurologic Disorders Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The neurologic disorders therapeutics market share growth by the CNS segment will be significant during the forecast period. Central nervous system (CNS) disorders are the indications that affect the nervous system comprising the brain and the spinal cord. CNS disorders can largely be classified into two categories, functional disorders and degeneration disorders, based on their nature and the affected area. The CNS segment of the global neurologic disorders therapeutics market is expected to benefit significantly from the recent drug approvals in the market for the treatment of various neurologic indications. This, in turn, will drive the neurologic disorders therapeutics market growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the neurologic disorders therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

Request for a FREE sample

What are the Key Data Covered in this Neurologic Disorders Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive neurologic disorders therapeutics market growth during the next five years
• Precise estimation of the neurologic disorders therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the neurologic disorders therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of neurologic disorders therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch